Importantly, a recent cost-effectiveness survey based upon the utilization of tPA, the only FDA-approved treatment for AIS [3] within 3–4.5 h after stroke onset, clearly showed that in AIS patients with National Institutes of Health Stroke Scale (NIHSS) scores of 0–19, there was an incremental benefit to the patient administered with tPA compared to patients with no treatment. This evidence concerns the gene PLAT and Stroke.